MxA-Guided Antiviral Treatment in Respiratory Viral Infections

Launched by CAPITAL MEDICAL UNIVERSITY · Oct 30, 2024

Keywords

ClinConnect Summary

This clinical trial is studying how effective a new treatment approach called MxA-guided antiviral treatment is for patients with respiratory viral infections, like influenza and COVID-19. The goal is to see if this method, which is based on the body’s own response to viruses, can help patients recover faster compared to standard antiviral treatments. The trial is currently looking for participants who are at least 18 years old and have been diagnosed with influenza or COVID-19 within the last 14 to 28 days, depending on the severity of their illness.

If you or someone you know is interested in participating, you should be aware that there are certain health conditions that could make someone ineligible, like being on a ventilator, having a weakened immune system, or having received certain treatments recently. Participants in the study will receive either the MxA-guided treatment or standard care and will be monitored closely for their health outcomes. This trial aims to help improve treatment options for respiratory viral infections in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • ≥ 18 years old
• • With a primary diagnosis of influenza or COVID-19 infection, diagnosed by a rapid antigen test or RT-PCR
• • Duration of infection ≤14 days for non-severe patients and \< 28 days for patients with severe infections
• • Currently receiving or planned to receive antiviral treatment, with the attending physician yet to decide on the discontinuation of the antiviral treatment
• Exclusion Criteria:
• • Current endotracheal intubation and mechanical ventilation
• • Current vasopressor use
• • Known immunosuppression
• • Received interferon therapy within 30 days before screening
• • Systemic inflammatory responses within 30 days prior to screening, such as cerebral infarction, myocardial infarction, or surgery
• • Received vaccine in the past 30 days
• • Active tuberculosis
• • With contraindications for antiviral treatment
• • Unable to obtain eligible samples
• • Co-infected with influenza and COVID-19